Wuxi Apptec Co., Ltd. Class A · SSE:603259
Wuxi Apptec Co., Ltd. Class A — J.P. Morgan Global Healthcare Conference 2021
24 slides from Wuxi Apptec Co., Ltd. Class A's conference presentation, Jan 13, 2021
Slide 1: WuXi AppTec
WuXi AppTec 603259.SH / 2359.HK J.P. Morgan Global Healthcare Conference January 13, 2021
Slide 2: Forward-Looking Statements; Non-IFRS Financial Measures
Forward-Looking Statements This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe
Slide 3: Our Vision
Our Vision “Every drug can be made and every disease can be treated” through building the open-access platform with the most comprehensive capabilities and technologies in the global healthcare industry Enabler of Innovation Trusted Partner Global Contributor
Slide 4: Our Solution: Integrated, End-to-End Enabling Platform
Our Solution: Integrated, End-to-End Enabling Platform Our open-access capabilities and technology platforms deliver quality service – and help customers and partners achieve their goals more quickly – by lowering the cost of research and development and shortening the time required to discover and
Slide 5: Business Units are Organized to Drive Segments Synergies
Business Units are Organized to Drive Segments Synergies Discovery Preclinical Clinical Manufacturing WuXi Research Service HitS IDSU Biology WuXi Testing DMPK/ADME Bioanalytical WuXi Clinical Toxicology Medical Device WuXi Chemistry Chemistry FFS (CSU) CDMO (STA) Success-based Services WuXi SMO Dom
Slide 6: 2020 Business Highlights
2020 Business Highlights “Long-Tail” Strategy Global Footprint 1,300+ New Customers 29 Global Sites & Branch Offices 4,200+ Active Customers 21,900+ Scientists & Technicians Loyal Customer Base Acquired Milestone Pharma to consolidate and expand capacity of our 100% Retention of Our analytical testi
Slide 7: Increase Customer Conversion to Drive Growth
Increase Customer Conversion to Drive Growth Contract Value & Duration Customer Stickiness 7% Q1-Q3’2020 Revenue Composition 52% China-based Lab 10% Clinical 31% Services US-based CDMO Lab Services Services 3% 2016 Revenue 53% Clinical 27% Composition China-based Lab 15% CDMO Services US-based Lab S
Slide 8: Accelerated Revenue & Profit Growth in Q3'2020
Accelerated Revenue & Profit Growth in Q3’2020 Revenue Adjusted Non-IFRS Net Profit RMB MM RMB MM 11,815 2,477 9,279 4,583 1,842 958 3,384 664 7,231 5,894 1,519 1,179 Q1-Q3'2019 Q1-Q3'2020 Q1-Q3'2019 Q1-Q3'2020 H1 Q3 H1 Q3 8
Slide 9: Our Platform & Business Model Continued to Perform Well
Our Platform & Business Model Continued to Perform Well Global Platform Strong, Loyal & Execute “Long-Tail” Increase Customer Enabling Innovation Expanding Strategy & Increase Our Conversion to Sustain Worldwide Customer Base Support to Large Pharma Growth Revenue Composition Revenue Composition Rev
Slide 10: Segment Revenue
Segment Revenue China-based Laboratory Services CDMO Services RMB MM RMB MM 6,473 3,752 3,710 6,118 5,113 4,672 2,699 2,717 4,121 2,338 1,548 2,109 999 Q3 1,683 Q3 H1 H1 3,780 1,718 2,162 2,989 2017 2018 2019 Q1-Q3'2019 Q1-Q3'2020 2017 2018 2019 Q1-Q3'2019 Q1-Q3'2020 US-based Laboratory Services Cli
Slide 11: Financial Performance
Financial Performance Revenue Non-IFRS Gross Profit Non-IFRS GPM RMB MM RMB MM 42.2% 40.3% 40.6% 41.0% 40.1% 12,872 11,815 9,614 9,279 5,259 4,743 7,765 4,583 3,893 3,384 3,835 1,826 Q3 3,277 Q3 1,438 7,231 H1 H1 5,894 2,397 2,918 2017 2018 2019 Q1-Q3'2019 Q1-Q3'2020 2017 2018 2019 Q1-Q3'2019 Q1-Q3'
Slide 12: Adjusted Non-IFRS Net Profit
Adjusted Non-IFRS Net Profit (1) RMB Million Q3’20 Q3’19 Q1-Q3’20 Q1-Q3’19 Net Profit Attributable to the Owners of the Company 651 708 2,368 1,765 Add: RMB MM Share-based compensation expenses 138 26 413 89 2,477 Convertible bonds issuance expenses 1 3 4 3 Fair value loss from derivative component
Slide 13: China-based Laboratory Services Highlights
China-based Laboratory Services Highlights Small Molecule Integrated Lab Capabilities Drug Discovery Testing Services & Capacities We developed COVID-19 small Q1-Q3’2020, signed 78 integrated New Chengdu R&D center molecule drug discovery platform very WIND packages with our customers, began o
Slide 14: Success-based Business Model With Potential Upside
Success-based Business Model With Potential Upside IND Filings For 1st In First 3 In 118 Our Customers ended Dec 31, 53 China1 85 China1 2020 193 Ongoing Projects Ended Dec 31,20202 Discovery & Pre-Clinical: 84 IND & beyond: 109 IND: 31 Clinical: 78 7 60 9 2 CTA P1 P2 P3 Notes: 1. Among China compan
Slide 15: Growing Small Molecule CDMO Project Pipeline
Growing Small Molecule CDMO Project Pipeline Added 575 New Molecules into the Pipeline 540 956 Preclinical & Phase I 32 Provided CDMO Services 217 Phase II to ~14% Global Win The Innovative Small Molecule Molecule 3 45 Phase III Drug Clinical Pipeline 28 Commercial Note: As of Dec 31, 2020 15
Slide 16: 1st Innovative Drug Commercial Project From API to DP
1st Innovative Drug Commercial Project From API to DP BTK Inhibitor Orelabrutinib Approved by NMPA Pre-Approval Inspections (Sept. 15 – Oct. 3rd) Record Setting for NMPA PAI 1st Drug product PAI R&D ASD Tablet DS Manufacturing Manufacturing Manufacturing Manufacturing Inspection for our spray drying
Slide 17: Cell and Gene Therapy CTDMO Services Highlights
Cell and Gene Therapy CTDMO1 Services Highlights Q3’2020 CGT CTDMO Backlog 2-3 products, including autologous cell QoQ Growth of therapy and allogeneic cell therapy products, are expected to file BLA in 2021. ~35% 2020 ATU projects 14 Plasmids, Lentivirus TIL / MIL AAV CAR-T Vectors & Others 38 Vect
Slide 18: Clinical Research CRO/SMO Services Highlights
Clinical Research CRO/SMO Services Highlights Capabilities & Capacity Backlog Projects SMO maintained #1 Q1-Q3’2020, SMO backlog Q1-Q3’2020, SMO assisted in leadership in China, with increased ~45% on a YoY the market approval of 14 3,300+ CRCs stationed in basis. products, including the 150 c
Slide 19: Anticipate the Industry Trend & Enable Global Innovations
Anticipate the Industry Trend & Enable Global Innovations New Modalities: Integrated Drug Discovery, Lab Testing and Manufacturing Platform Drug Discovery DEL PROTAC Peptide Oligo PDC Diseases Targets ADC Integrated Cell Oncolytic Molecules Testing CDMO Therapy Virus Platform Gene Therapy 19
Slide 20: Growing Talents for Sustaining Business Growth
Growing Talents for Sustaining Business Growth Rapid Expansion of Talent Base Employees As of 26,240 Dec 31, 2020 1,783 Oversea 26,240 21,744 17,730 14,763 11,422 Research & CDMO1 21,942 Development 7,845 2016 2017 2018 2019 2020 Note: 1. Including small molecule CDMO & cell and gene therapies CTDMO
Slide 21: Global Capacity Expansion to Drive Strong Growth for 2021 & Beyond
Global Capacity Expansion to Drive Strong Growth for 2021 & Beyond China-based Laboratory Services: • Build a new site in Nantong, Jiangsu Province for drug safety testing (toxicology) and laboratory testing services. • Build a new site in Wuhan to expand discovery chemistry and new modality service
Slide 22: Capacity in Progress
Capacity in Progress Jinshan Wuxi Tianjin Nantong Munich Minnesota Changzhou New Jersey Suzhou San Diego Philadelphia Chengdu Wuhan The Capacity of Our Sites is Expanding Shanghai k m2 1,200 1,132 1,000 943 768 800 622 600 545 400 ~1,132K m2 of Laboratories, Manufacturing 200 Facilities and Offices
Slide 23: We Are Achieving Strong Growth in 2020 and Continue to Invest for Future Growth
We Are Achieving Strong Growth in 2020 and Continue to Invest for Future Growth 1 We Won Back 2020 Despite the COVID-19 Pandemic Caused Challenges. We will Maintain Strong Growth Momentum in 2021 Through Our “Long-tail” 2 and “Follow the Customer, Follow the Molecule” Strategies. 3 We will Continue
Slide 24: Thank You!
Thank You! G l o b a l P l a t f o r m . O n e V i s i o n . 2424 www.wuxiapptec.com
WuXi AppTec — J.P. Morgan Global Healthcare Conference 2021 on 6ix